（2）创新药方面，2~3月为港股药企业绩披露窗口，多家有望迎来减亏或扭亏；展望全年，AACR(4 月)、ASCO(5月)、ESMO(10月)等学术会议渐次到来，国产创新药有望进一步带来临床数据的兑现。 关注港股通科技ETF基金（159101.SZ）及其联接C（025806.OF），被动跟踪国证港股通科技指数，该 指数在恒生科技基础上，龙头权重更集中（阿里巴巴、腾讯控股合计占比30%），同时兼顾创新药龙头 （药明生物/信达生物/康方生物）。港股通科技ETF基金（159101.SZ）在深圳证券交易所上市，并支持 T+0日内灵活回转交易，为A股投资者提供低门槛、免开跨境户和免换汇的便利。 2月10日盘初，港股AI应用、创新药板块延续昨日涨势。阅文集团、智谱涨超6%，快手-W涨超4%，药 明生物、康方生物、信达生物涨超2%，港股通科技ETF基金（159101.SZ）盘中涨1%。 综合招商证券、国金证券等机构观点，港股科技资产前期回调较为充分，后市催化增多： （1）AI应用方面，腾讯、阿里纷纷在春节期间进行大模型宣传、快手可灵年化ARR超预期、DeepSeek 或在春节期间发布最新V4大模型。 ...

Group 1: Market Activity - Hong Kong pharmaceutical stocks remain active, with Innovent Biologics experiencing a significant surge following an $8.85 billion business development deal, rising 5% after a previous 7.42% increase [1][7] - Other companies such as Zai Lab, CSPC Pharmaceutical, and Rongchang Biologics also saw substantial gains [1][7] - The Hong Kong Stock Connect Innovation Drug ETF (520880) rose over 2% during trading, recovering above the 20-day moving average [1][7] Group 2: Industry Trends - The total transaction scale for China's innovative drug license-out reached a record $135.7 billion in 2025, with significant collaborations in January 2026, including a $18.5 billion deal between CSPC and AstraZeneca, and a $5.6 billion deal between Rongchang and AbbVie, highlighting the global value of domestic innovative drug pipelines [9] - The innovative drug sector is transitioning from "scale accumulation" to "value release," with a focus on commercial realization of pipeline expectations [9] - The innovative drug sector has seen a correction over the past two quarters, but many quality stocks now offer attractive valuations, suggesting increased attention is warranted [9] Group 3: Investment Recommendations - Analysts recommend focusing on high-growth and improving expectation sectors within the pharmaceutical industry, as the impact of medical insurance cost control has been fully reflected [11] - The Hong Kong Stock Connect Innovation Drug ETF (520880) and its associated funds are highlighted for their 100% focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [11] - The Hong Kong Stock Connect Medical ETF (159137) is suggested for its coverage of innovative medical concepts, including brain-computer interfaces and AI healthcare, while also encompassing leading companies across the entire innovative drug supply chain [11]

Group 1 - The core viewpoint of the articles indicates that the recent volatility in Hong Kong's technology sector, with the Hang Seng Tech Index dropping 6.5% in a week, is primarily due to liquidity shocks, but the outlook for investing in Hong Kong tech stocks remains positive with high odds and win rates [1] - From the perspective of odds, the discount of Hong Kong tech stocks relative to A-share tech stocks is near historical lows, suggesting significant undervaluation, especially in the context of improved regulatory and economic conditions compared to 2022 and 2023 [1] - In terms of win rates, favorable factors are accumulating, including the peak of overseas liquidity shocks having passed, the effectiveness of the "buy the dip" strategy, and the potential for a rebound as the relative valuation of Hong Kong tech stocks approaches historical lows [1] Group 2 - Investment opportunities in Hong Kong tech-related ETFs are highlighted, including the Hang Seng Tech Index ETF (513180.SH), Hang Seng Internet ETF (513330.SH), and Hong Kong Stock Connect Tech ETF (159101.SZ), which provide low-threshold access for A-share investors [2] - The Hang Seng Internet ETF (513330.SH) focuses on major Hong Kong internet companies such as Alibaba, Baidu, Tencent, and NetEase, while the Hong Kong Stock Connect Tech ETF (159101.SZ) emphasizes leading companies and includes innovative pharmaceutical stocks [2] - These ETFs are listed on mainland stock exchanges and support T+0 intraday trading, offering convenience for investors without the need for cross-border accounts or currency exchange [2]

Group 1: Pharmaceutical Industry - The pharmaceutical index increased by 0.14%, outperforming the CSI 300 index by 1.47% during the week [2][6] - The report highlights the potential of molecular glue technology to target "undruggable" proteins, expanding the scope for innovative drug development [8][9] - Recommended stocks in the innovative drug sector include Heng Rui Medicine, China Biologic Products, and Yuan Dong Biology, among others [11][9] Group 2: Construction and Building Materials - Major engineering projects are identified as a key focus for the "14th Five-Year Plan," with significant investments planned across various provinces [13][14] - The report notes that infrastructure projects will dominate investment, with substantial funding allocated to transportation, municipal, and energy sectors [14] - The issuance of special bonds has increased significantly, with a total of 5,164.55 billion yuan issued as of February 8, 2026, marking a year-on-year increase of 125.35% [15] Group 3: Real Estate - The Shanghai government has initiated the acquisition of second-hand homes for rental housing projects, indicating a strategic move to stabilize the real estate market [19][21] - New home sales in 42 key cities totaled 1.48 million square meters, a slight decrease of 0.1% week-on-week, while second-hand home sales fell by 3.0% [20][19] - The report suggests that the real estate market is entering a phase of structural differentiation, with high-quality housing expected to see increased demand [23] Group 4: Overseas and Education Research - The first round of negotiations between the US and Iran concluded, with market sentiment shifting towards risk assets, particularly in AI and commercial aerospace sectors [26][30] - Bloom Energy reported better-than-expected earnings, with Q4 2025 revenue reaching $777.8 million, a year-on-year increase of 35.9% [26] - The quantum computing sector is gaining attention, with NERSC announcing a call for proposals utilizing neutral atom quantum processors [28]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15] - The implementation plan for the high-quality development of the TCM industry (2026-2030) aims to establish a collaborative development system for the entire industry chain by 2030, fostering leading TCM enterprises and promoting the approval of innovative TCM drugs [4][15] - The report identifies specific companies that are expected to benefit from these policies, including Yiling Pharmaceutical, Tianshili, Kangyuan Pharmaceutical, and Fangsheng Pharmaceutical [5][16][17] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a 52-week high of 9323.49 and a low of 6876.88 [1] Recent Market Performance - During the week of February 2 to February 6, 2026, the A-share pharmaceutical and biotechnology sector rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points and the ChiNext index by 3.43 percentage points [6][18] - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline of 2.42% [18] Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is expected to continue to be a strong growth area, with a focus on companies with high certainty and relatively low business development (BD) expectation disturbances, such as Innovent Biologics, Sanofi, and others [7][21] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies improving their performance in Q3. The report suggests that the pressure from centralized procurement is diminishing, which may lead to valuation recovery [8][23] 3. **Traditional Chinese Medicine**: The report is optimistic about TCM companies benefiting from centralized procurement and basic drug policies, with specific companies highlighted for their potential growth [29][30] 4. **AI in Healthcare**: Companies leveraging AI technology in drug development and medical services are expected to see significant benefits, with specific companies listed for each AI application area [9][32][34]

Group 1 - The Hong Kong stock market experienced a comprehensive rebound, with the pharmaceutical sector continuing its recovery trend, led by Innovent Biologics, which secured an $8.85 billion business development deal, resulting in a daily increase of 7.42% [1][3] - Other leading stocks such as BeiGene, CSPC Pharmaceutical Group, and 3SBio also saw gains, contributing to the overall positive sentiment in the market [1] - The Hong Kong Stock Connect Innovation Drug ETF (520880) opened high and rose by 1.77%, successfully maintaining an upward trend and surpassing the 10-day moving average, with a total transaction volume of 381 million yuan [1] Group 2 - On February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3] - The total transaction scale for licensing out innovative drugs in China is expected to reach a record $135.7 billion by 2025, with significant collaborations emerging in early 2026, validating the global value of domestic innovative drug pipelines [3] - The Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," with a focus on commercial realization, indicating a favorable long-term outlook for quality stocks in the sector [3] Group 3 - The Hong Kong medical device sector is characterized by strong innovation, with several companies showing improved operational performance and attractive investment value due to low valuations [5] - Companies like Mindray and Kefu Medical are expected to go public in Hong Kong this year, potentially increasing investment opportunities within the medical device sector [5] - The recommendation is to invest in the Hong Kong Stock Connect Innovation Drug ETF (520880) and the Hong Kong Stock Connect Medical ETF (159137), which focus on innovative drug development and encompass various hot concepts such as AI healthcare and internet pharmacies [5]

Group 1 - The Hong Kong stock market experienced a comprehensive rebound on February 9, with the pharmaceutical sector continuing its recovery trend, led by Innovent Biologics, which secured an $8.85 billion BD deal, resulting in a peak increase of 8.55% and a closing rise of 7.42% [1][3] - Other leading stocks such as BeiGene rose over 3%, while CSPC Pharmaceutical, China Biologic Products, and 3SBio also saw collective gains [1][3] - The Hong Kong Stock Connect Innovation Drug ETF (520880) opened high, reaching an increase of 2.75% and closing up 1.77%, successfully maintaining an upward trend and surpassing the 10-day moving average with a total transaction volume of 381 million yuan [1][3] Group 2 - On the evening of February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3] - The total transaction scale for China's innovative drug License-out is expected to reach a record $135.7 billion by 2025, with significant collaborations emerging in 2026, including major deals involving CSPC and AstraZeneca ($18.5 billion) and Rongchang and AbbVie ($5.6 billion), validating the global value of domestic innovative drug pipelines [3] - According to Open Source Securities, the Chinese innovative drug sector is transitioning from "scale accumulation" to "value release," entering a commercialization harvest period, with many quality targets showing significant valuation attractiveness after nearly two quarters of correction [3] Group 3 - The Hong Kong Stock Connect medical sector showed active performance, particularly in AI medical and brain-computer interface concept stocks, with major players like JD Health, Alibaba Health, and Ping An Good Doctor all rising around 3% [3] - The AI medical sector is rapidly penetrating the consumer end, expanding application scenarios from smart consultations to chronic disease management, leading to a revaluation of internet medical platforms like Alibaba Health and JD Health [3] Group 4 - CITIC Securities noted that the overall innovation attribute of the Hong Kong medical device sector is strong, with some companies' innovative products having potential for license-out or acquisition [5] - The fundamentals of most companies in the industry are continuously improving, highlighting the investment value of low valuations [5] - It is anticipated that Mindray Medical and Caresyntax will be listed in Hong Kong this year, potentially increasing investment opportunities in the Hong Kong medical device sector [5]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1]. Core Insights - The report highlights the acceleration of policy support for the optimization and transformation of the traditional Chinese medicine (TCM) industry, benefiting leading TCM companies [4][15]. - The report emphasizes the potential benefits for innovative drug companies due to the establishment of a collaborative innovation system and the promotion of new drug approvals [5][15]. - The report notes that the A-share pharmaceutical and biotechnology sector has shown a slight increase of 0.14% in the week from February 2 to February 6, 2026, outperforming the CSI 300 index by 1.47 percentage points [6][18]. Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8350.08, with a weekly high of 9323.49 and a low of 6876.88 [1]. Recent Market Performance - The A-share pharmaceutical sector outperformed the CSI 300 index and the ChiNext index during the week, ranking 15th among 31 sub-industries [6][18]. - The TCM sector ranked first among sub-sectors with a weekly increase of 2.56%, while other biopharmaceutical sectors experienced a decline [18]. Policy Developments - The Ministry of Industry and Information Technology and other departments issued a plan for the high-quality development of the TCM industry from 2026 to 2030, aiming to establish a collaborative development system and support leading TCM enterprises [4][15]. - The plan includes fostering a batch of innovative TCM drugs and enhancing the protection of intellectual property for traditional brands [5][16][17]. Investment Recommendations 1. **Innovative Drugs**: The report suggests that innovative drug companies remain a strong investment choice, with a focus on companies with high certainty and low disruption expectations, such as Innovent Biologics and 3SBio [7][21]. 2. **Medical Devices**: The medical device sector is expected to see a recovery in profits, with a focus on companies like Mindray and Kangji Medical, as the impact of centralized procurement diminishes [23][24]. 3. **Traditional Chinese Medicine**: Companies like Yiling Pharmaceutical and Tianjin Zhongxin Pharmaceutical are expected to benefit from policies supporting TCM and the clearing of high inventory levels [28][29][30]. 4. **AI in Healthcare**: Companies involved in AI applications in pharmaceuticals and diagnostics, such as iCarbonX and Huada Gene, are anticipated to benefit from advancements in AI technology [32][34].

Group 1 - Global assets are experiencing significant volatility at the beginning of 2026, with precious metals like gold and silver showing notable pullbacks after initial gains [1][19] - The market is focused on how to allocate assets after the turbulence, particularly regarding fixed income assets as a long-term core allocation [1][19] - The current political climate is shifting towards a "big fiscal" era, with abundant liquidity leading to asset bubbles, particularly in the U.S. stock market [19][21] Group 2 - The U.S. market is entering a bubble phase similar to 1999, with expectations for gold to reach new highs while the dollar index declines [2][19] - Key risks for 2026 include potential loss of Federal Reserve independence, aggressive monetary easing leading to inflation, and possible internal strife in the U.S. [2][19] - If risks arise outside the U.S., dollar assets may serve as a safe haven, similar to the situation in 1998 [2][19] Group 3 - Investors are advised to adopt a diversified asset allocation strategy for 2026, including A-shares, Hong Kong stocks, U.S. stocks, commodities, and bonds, with a focus on a "core + satellite" structure [4][21] - The core investment should be in the CSI A500 ETF, which is expected to outperform traditional indices, while satellite investments should include technology growth and cash flow/dividend assets [4][21] - The main theme for 2026 remains artificial intelligence, with a focus on sectors like communication and semiconductor ETFs [4][21] Group 4 - In equity investments, there is optimism for a shift from valuation recovery to profit improvement, particularly in sectors like non-ferrous metals, new energy, and chemicals [8][24] - Fixed income investments are expected to maintain a positive stance, with a focus on credit strategies and potential trading opportunities as the market adjusts [8][24] - The credit bond market is anticipated to experience wide fluctuations, with a focus on short-term strategies and market sentiment [10][26] Group 5 - The economic environment remains under pressure, with weak consumer demand and a declining real estate market, leading to low inflation expectations [12][28] - Monetary policy is expected to remain accommodative, with potential for further rate cuts and reserve requirement reductions in 2026 [12][28] - Institutional behavior indicates a strong performance in equity markets, but challenges remain for public funds and banks in expanding their balance sheets [12][28]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4][47]. Core Viewpoints - The pharmaceutical market showed a slight increase of 0.14% from February 2 to February 6, with a relative outperformance of 1.47% compared to the CSI 300 index. The report suggests focusing on strong fundamental innovative drug stocks and highlights the potential for recovery in the innovative drug sector [5][16]. - The report emphasizes the significance of molecular glue technology in expanding the druggable target space, particularly for "undruggable targets," and suggests monitoring the progress of related drugs from Yuandong Biotech [3][8]. - The report outlines a positive outlook for the pharmaceutical industry in 2026, driven by technological innovation and performance/valuation recovery, with a focus on innovative drugs, AI medical technology, and the aging population's healthcare needs [36][37]. Summary by Sections Market Performance - The pharmaceutical index increased by 0.14% during the specified week, with 253 stocks rising and 206 falling. Top gainers included Guangshengtang (+29.83%) and Haixiang Pharmaceutical (+18.64%), while major losers included Changshan Pharmaceutical (-15.78%) and Shuanglu Pharmaceutical (-13.95%) [5][16][17][18]. Molecular Glue Technology - Molecular glue targets undruggable proteins, with only about 3.5% of human proteins confirmed as druggable. The report highlights Yuandong Biotech's advancements in this area, particularly their product HP-001, which shows promising clinical data and potential as a "Best-in-Class" treatment [8][12][13]. Investment Recommendations - The report recommends focusing on innovative drug companies such as Heng Rui Pharmaceutical, China Biologic Products, and Yuandong Biotech, as well as companies involved in AI medical technology and healthcare for the aging population [36][39]. Industry Trends - The report identifies key trends such as the acceleration of the aging population, the growth of chronic disease demand, and the increasing importance of commercial insurance in the healthcare payment system. It also notes the potential for new growth drivers from AI and brain-computer interface technologies [36][37]. Valuation Insights - As of February 6, 2026, the overall PE valuation for the pharmaceutical sector is 37.31X, indicating a relatively low historical position. The report suggests that various sub-sectors have differing valuation levels, with some being relatively high and others low [25][32]. Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve in 2026, with a focus on innovative drugs and technologies. It suggests that structural growth opportunities will emerge, particularly in the context of the global healthcare landscape [36][37].